Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer

Running, not enrolling

Conditions studied: Invasive Breast Carcinoma

In brief

This early phase I trial evaluates the impact of chemotherapy before surgery (neoadjuvant) on the peripheral blood immune phenotype in patients with operable breast cancer. Collecting blood and information from patients with breast cancer may help to understand how the immune system influences response to treatment, and how the immune system reacts to breast cancer treatment.

Key facts

Study ID

NCT04897009

Run by

Mayo Clinic

People needed

38

Starts

2021-06-09

Expected to finish

2028-06-08

Last updated by the study team

2026-02-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >= 18 years
• Histologically confirmed, operable, invasive breast cancer. Note: Patients with oligometastatic breast cancer (up to 3 isolated distant metastases) will be eligible after review and approval by principal investigator (PI)
• Recommended to receive neoadjuvant systemic treatment by their primary medical oncologist and planning to receive one of the regimens
• Provide written informed consent
• Willing to return to Mayo Clinic for breast cancer surgery
• Willingness to provide mandatory blood specimens for future research on breast cancer at Mayo Clinic

You may not qualify if…

• Patients who have already initiated neoadjuvant chemotherapy for the current malignancy
• Inability to provide blood samples based on the judgement of the treating physician
• Inability to comply with the protocol
• Patient is pregnant or plans to become pregnant

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.